KR20220023330A - Prmt5 억제제 및 이의 용도 - Google Patents
Prmt5 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20220023330A KR20220023330A KR1020217034437A KR20217034437A KR20220023330A KR 20220023330 A KR20220023330 A KR 20220023330A KR 1020217034437 A KR1020217034437 A KR 1020217034437A KR 20217034437 A KR20217034437 A KR 20217034437A KR 20220023330 A KR20220023330 A KR 20220023330A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823374P | 2019-03-25 | 2019-03-25 | |
| US62/823,374 | 2019-03-25 | ||
| US201962874773P | 2019-07-16 | 2019-07-16 | |
| US62/874,773 | 2019-07-16 | ||
| PCT/US2020/024654 WO2020198323A1 (en) | 2019-03-25 | 2020-03-25 | Prmt5 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220023330A true KR20220023330A (ko) | 2022-03-02 |
Family
ID=72609147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217034437A Ceased KR20220023330A (ko) | 2019-03-25 | 2020-03-25 | Prmt5 억제제 및 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12583859B2 (https=) |
| EP (1) | EP3947387B1 (https=) |
| JP (1) | JP7609798B2 (https=) |
| KR (1) | KR20220023330A (https=) |
| CN (1) | CN114127072B (https=) |
| AU (1) | AU2020245480A1 (https=) |
| BR (1) | BR112021019125A2 (https=) |
| CA (1) | CA3134779A1 (https=) |
| IL (2) | IL318073A (https=) |
| MX (1) | MX2021011524A (https=) |
| SG (1) | SG11202110272SA (https=) |
| WO (1) | WO2020198323A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| IL318073A (en) | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| CN117157297A (zh) * | 2021-07-20 | 2023-12-01 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
| EP4458836A4 (en) * | 2021-12-27 | 2025-05-21 | Riken Genesis Co., Ltd. | Novel artificial nucleic acid, method for producing same, and use of same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| KR102028793B1 (ko) | 2013-03-14 | 2019-10-07 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) * | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018160824A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP3939986A1 (en) * | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US11059850B2 (en) * | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
| IL318073A (en) | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
-
2020
- 2020-03-25 IL IL318073A patent/IL318073A/en unknown
- 2020-03-25 MX MX2021011524A patent/MX2021011524A/es unknown
- 2020-03-25 KR KR1020217034437A patent/KR20220023330A/ko not_active Ceased
- 2020-03-25 SG SG11202110272SA patent/SG11202110272SA/en unknown
- 2020-03-25 EP EP20778402.6A patent/EP3947387B1/en active Active
- 2020-03-25 CA CA3134779A patent/CA3134779A1/en active Pending
- 2020-03-25 AU AU2020245480A patent/AU2020245480A1/en not_active Abandoned
- 2020-03-25 BR BR112021019125A patent/BR112021019125A2/pt not_active IP Right Cessation
- 2020-03-25 CN CN202080037608.5A patent/CN114127072B/zh active Active
- 2020-03-25 JP JP2021557342A patent/JP7609798B2/ja active Active
- 2020-03-25 WO PCT/US2020/024654 patent/WO2020198323A1/en not_active Ceased
- 2020-03-25 US US17/598,152 patent/US12583859B2/en active Active
-
2021
- 2021-09-23 IL IL286622A patent/IL286622A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3947387B1 (en) | 2024-10-23 |
| MX2021011524A (es) | 2021-12-15 |
| CN114127072A (zh) | 2022-03-01 |
| US20220194949A1 (en) | 2022-06-23 |
| BR112021019125A2 (pt) | 2021-11-30 |
| IL318073A (en) | 2025-02-01 |
| CN114127072B (zh) | 2024-10-11 |
| JP7609798B2 (ja) | 2025-01-07 |
| EP3947387A4 (en) | 2022-11-30 |
| WO2020198323A1 (en) | 2020-10-01 |
| SG11202110272SA (en) | 2021-10-28 |
| JP2022521818A (ja) | 2022-04-12 |
| AU2020245480A1 (en) | 2021-11-11 |
| US12583859B2 (en) | 2026-03-24 |
| CA3134779A1 (en) | 2020-10-01 |
| EP3947387A1 (en) | 2022-02-09 |
| IL286622A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114127072B (zh) | Prmt5抑制剂及其用途 | |
| JP7502337B2 (ja) | Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 | |
| WO2022028506A1 (zh) | Sos1抑制剂、包含其的药物组合物及其用途 | |
| JP2022522534A (ja) | Ｐｒｍｔ５を標的にする化合物 | |
| TW202200574A (zh) | Bcl-2抑制劑 | |
| US9820972B2 (en) | Antiviral compounds highly effective as HCV-NS5A inhibitor | |
| CN115504980B (zh) | 嘧啶并含氮六元芳香杂环类化合物及其用途 | |
| CN109867675A (zh) | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 | |
| KR20220042127A (ko) | 피라졸로피리미딘 화합물, 그의 제조 방법 및 그의 응용 | |
| US9724331B2 (en) | Use of maleimide derivatives for preventing and treating leukemia | |
| WO2022227987A1 (zh) | 杂环类衍生物及其制备方法和用途 | |
| KR102833011B1 (ko) | 푸로[3,4-b]피롤-함유 BTK 억제제 | |
| WO2020247679A1 (en) | Wdr5 inhibitors and modulators | |
| HK40063243B (en) | Prmt5 inhibitors and uses thereof | |
| HK40063243A (en) | Prmt5 inhibitors and uses thereof | |
| EP4038072A1 (en) | Mcl1 inhibitors and uses thereof | |
| JP7738668B2 (ja) | ダブルリング雑環ｆｇｆｒ４阻害剤、ダブルリング雑環ｆｇｆｒ４阻害剤を含有する医薬組成物と製剤、及びその用途 | |
| WO2025201453A1 (en) | Macrocyclic compounds as ras inhibitors | |
| IL321757A (en) | Naphthylamide compound, and preparation method therefor and use thereof | |
| CN120058741A (zh) | Dgk抑制剂化合物及其应用 | |
| CN119100968A (zh) | 一种抑制tead活性的并环化合物、其制备方法及应用 | |
| OA19533A (en) | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors. | |
| WO2019196780A1 (zh) | 一种新型吲哚胺2，3-双加氧酶抑制剂及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |